Literature DB >> 6084774

Beta 1-selectivity of bisoprolol, a new beta-adrenoceptor antagonist, in anesthetized dogs and guinea pigs.

H J Schliep, J Harting.   

Abstract

The beta-adrenoceptor activity of the newly synthesized antagonist bisoprolol [+/-)-1-[4-(2-isopropoxyethoxymethyl)-phenoxy]-3-isopropylamino-2- propranol, hemifumarate), has been compared with the effect of several reference compounds in anesthetized dogs and guinea pigs. In anesthetized, bivagotomized dogs, isoprenaline dose-response relations for increase in heart rate and decrease in diastolic blood pressure were established. Bisoprolol had the largest beta 1/beta 2 ratio, i.e., 147 (102-292). Practolol showed a beta 1/beta 2 ratio greater than 17; betaxolol 6-15; acebutolol, atenolol, and metoprolol 1.1-3.2; mepindolol 0.6-1 and propranolol 0.2. In artificially ventilated guinea pigs, the activity of bisoprolol on histamine-induced increase in tracheal lateral pressure (TLP) and basal heart rate (HR) was tested: using doses taken at TLP (30 mm Hg) and HR (250 beats/min), bisoprolol exhibited the most pronounced ratio TLP/HR of 124 +/- 59, followed by atenolol 33 +/- 23, metoprolol 25 +/- 15, betaxolol 12 +/- 4, propranolol 1 +/- 0.3, and celiprolol 0.23 +/- 0.19. These experiments indicate that bisoprolol possesses a pronounced beta 1-selectivity, which seems to be superior to that of known beta 1-selective antagonists.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6084774

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  18 in total

Review 1.  Bisoprolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and angina pectoris.

Authors:  S G Lancaster; E M Sorkin
Journal:  Drugs       Date:  1988-09       Impact factor: 9.546

2.  Effect of bisoprolol on cardiac performance in coronary heart disease.

Authors:  B Maisch; U Borst; W Gerhards; G Wagner
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

3.  Bolus application of landiolol and esmolol: comparison of the pharmacokinetic and pharmacodynamic profiles in a healthy Caucasian group.

Authors:  Günther Krumpl; Ivan Ulc; Michaela Trebs; Pavla Kadlecová; Juri Hodisch
Journal:  Eur J Clin Pharmacol       Date:  2017-01-13       Impact factor: 2.953

4.  Comparative effects of bisoprolol and acebutolol in smokers with airway obstruction.

Authors:  I Macquin-Mavier; F Roudot-Thoraval; C Clerici; C George; A Harf
Journal:  Br J Clin Pharmacol       Date:  1988-09       Impact factor: 4.335

5.  Effects of bisoprolol on blood pressure, serum lipids and HDL-cholesterol in essential hypertension.

Authors:  G Frithz; L Weiner
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

6.  Hemodynamic evaluation of bisoprolol after coronary artery surgery in patients with altered left ventricular function.

Authors:  M Goldstein; J L Vincent; J L Le Clerc; A d'Hollander; C Melot; R J Kahn
Journal:  Cardiovasc Drugs Ther       Date:  1991-06       Impact factor: 3.727

7.  Pharmacokinetics of bisoprolol during repeated oral administration to healthy volunteers and patients with kidney or liver disease.

Authors:  W Kirch; I Rose; H G Demers; G Leopold; J Pabst; E E Ohnhaus
Journal:  Clin Pharmacokinet       Date:  1987-08       Impact factor: 6.447

8.  Pharmacological actions of the selective and non-selective beta-adrenoceptor antagonists celiprolol, bisoprolol and propranolol on human bronchi.

Authors:  R W Hauck; C Schulz; H P Emslander; M Böhm
Journal:  Br J Pharmacol       Date:  1994-11       Impact factor: 8.739

9.  A double-blind comparison of bisoprolol and captopril for treatment of essential hypertension in the elderly.

Authors:  D Bracchetti; R Gradnik; A Alberti; A Brunelli; L Orselli; G Leonardi; P C Pavesi; I Cantelli
Journal:  Cardiovasc Drugs Ther       Date:  1990-02       Impact factor: 3.727

10.  Beta-adrenoceptor antagonists (non-selective as well as beta 1-selective) with partial agonistic activity decrease beta 2-adrenoceptor density in human lymphocytes. Evidence for a beta 2-agonistic component of the partial agonistic activity.

Authors:  O E Brodde; R Schemuth; M Brinkmann; X L Wang; A Daul; U Borchard
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-06       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.